Optina Diagnostics

Optina Diagnostics is a Montreal, Canada-based diagnostic company focused on retinal imaging, brain health, and systemic disease detection. It has developed technology for early non-invasive disease detection through its Retinal Deep Phenotyping™ platform. Under the leadership of CEO David Lapointe, Optina Diagnostics is advancing the Retinal Deep Phenotyping™ platform, which received FDA Breakthrough Device Designation in 2019. Its first indication is a non-invasive and more accessible test to enhance diagnostic accuracy and management evaluation for patients undergoing treatment for Alzheimer's disease (AD). In 2020, the company also received 501(k) clearance for its hyperspectral Optina-4C™ camera.